Incannex is undertaking four clinical trials in 2020 for the creation of four distinct products with clinical evidence.

Under the guidance of our new medical advisory board, IHL has commenced the full drug discovery process for cannabinoid products for OSA, TBI, SAARDS and TMJD.

The expanded clinical program will create 4 novel products for which patents have been or are in the process of being filed.